Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emicizumab for the treatment of Haemophilia A

Trial Profile

Emicizumab for the treatment of Haemophilia A

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Emicizumab (Primary) ; Eptacog alfa; Factor VIII inhibitor bypassing fraction
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top